{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:57:31Z","timestamp":1793228251561,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Natural Science Foundation of Jiangsu province","award":["BK20211027"],"award-info":[{"award-number":["BK20211027"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-1-I2M-018, 2021-I2M-1-001, 2021-I2M-1-059"],"award-info":[{"award-number":["2021-1-I2M-018, 2021-I2M-1-001, 2021-I2M-1-059"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03658-x","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T14:16:10Z","timestamp":1734704170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Repigmentation in non-segmental vitiligo using the Janus kinase inhibitor upadacitinib, a retrospective case series"],"prefix":"10.1007","volume":"317","author":[{"given":"Jing","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengrang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"3658_CR1","doi-asserted-by":"publisher","unstructured":"Frisoli ML, Essien K, Harris JE, Vitiligo (2020) Mechanisms of pathogenesis and treatment. Annu Rev Immunol 38:621\u2013648. https:\/\/doi.org\/10.1146\/annurev-immunol-100919-023531","DOI":"10.1146\/annurev-immunol-100919-023531"},{"issue":"2","key":"3658_CR2","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","volume":"74","author":"JE Harris","year":"2016","unstructured":"Harris JE, Rashighi M, Nguyen N, Jabbari A, Ulerio G, Clynes R, Christiano AM, Mackay-Wiggan J (2016) Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol 74(2):370\u2013371. https:\/\/doi.org\/10.1016\/j.jaad.2015.09.073","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3658_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00403-014-1515-1","volume":"307","author":"VM Sheth","year":"2015","unstructured":"Sheth VM, Gunasekera NS, Silwal S, Qureshi AA (2015) Development and pilot testing of a vitiligo screening tool. Arch Dermatol Res 307(1):31\u201338. https:\/\/doi.org\/10.1007\/s00403-014-1515-1","journal-title":"Arch Dermatol Res"},{"issue":"7","key":"3658_CR4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.adengl.2021.05.008","volume":"112","author":"C Garcia-Melendo","year":"2021","unstructured":"Garcia-Melendo C, Cubir\u00f3 X, Puig L (2021) Janus kinase inhibitors in dermatology: part 2: applications in psoriasis, atopic dermatitis, and other dermatoses. Actas Dermosifiliogr (Engl Ed) 112(7):586\u2013600. https:\/\/doi.org\/10.1016\/j.adengl.2021.05.008","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"4","key":"3658_CR5","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","volume":"77","author":"LY Liu","year":"2017","unstructured":"Liu LY, Strassner JP, Refat MA, Harris JE, King BA (2017) Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol 77(4):675\u2013682e1. https:\/\/doi.org\/10.1016\/j.jaad.2017.05.043","journal-title":"J Am Acad Dermatol"},{"key":"3658_CR6","doi-asserted-by":"publisher","first-page":"106362","DOI":"10.1016\/j.phrs.2022.106362","volume":"183","author":"R Roskoski Jr","year":"2022","unstructured":"Roskoski R Jr. (2022) Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders. Pharmacol Res 183:106362. https:\/\/doi.org\/10.1016\/j.phrs.2022.106362","journal-title":"Pharmacol Res"},{"issue":"6","key":"3658_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4132\/jptm.2018.09.18","volume":"52","author":"AG Abdou","year":"2018","unstructured":"Abdou AG, Maraee A, Yassien H, Sarhan M (2018) Immunohistochemistry of Janus kinase 1 (JAK1) expression in vitiligo. J Pathol Transl Med 52(6):363\u2013368. https:\/\/doi.org\/10.4132\/jptm.2018.09.18","journal-title":"J Pathol Transl Med"},{"key":"3658_CR8","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jdin.2023.06.008","volume":"16","author":"A Pourang","year":"2024","unstructured":"Pourang A, Kohli I, Ezekwe N, Parks-Miller A, Mohammad TF, Huggins RH, Lim HW, Deal LS, Lukic T, Zhang F, Hamzavi I (2024) Reliability of the vitiligo area scoring index measurement tool for vitiligo. JAAD Int 16:206\u2013213. https:\/\/doi.org\/10.1016\/j.jdin.2023.06.008","journal-title":"JAAD Int"},{"issue":"6","key":"3658_CR9","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.jaad.2023.07.1016","volume":"89","author":"X Su","year":"2023","unstructured":"Su X, Luo R, Ruan S et al (2023) Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo. J Am Acad Dermatol 89(6):1257\u20131259. https:\/\/doi.org\/10.1016\/j.jaad.2023.07.1016","journal-title":"J Am Acad Dermatol"},{"key":"3658_CR10","doi-asserted-by":"publisher","unstructured":"Zhu Y, Shi Z, Xu Z et al (2024) Oral tofacitinib, baricitinib and upadacitinib monotherapy for steroid-resistant vitiligo: a prospective case series. J Eur Acad Dermatol Venereol. Published online June 10. https:\/\/doi.org\/10.1111\/jdv.20109","DOI":"10.1111\/jdv.20109"},{"issue":"9","key":"3658_CR11","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/bjd.14416","volume":"174","author":"XX Wang","year":"2016","unstructured":"Wang XX, Wang QQ, Wu JQ et al (2016) Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo.J. Br J Dermatol 174(9):1318\u20131326. https:\/\/doi.org\/10.1111\/bjd.14416","journal-title":"Br J Dermatol"},{"issue":"18","key":"3658_CR12","doi-asserted-by":"publisher","first-page":"5861","DOI":"10.3390\/jcm12185861","volume":"12","author":"A Kassab","year":"2023","unstructured":"Kassab A, Khalij Y, Ayed Y et al (2023) Serum inflammatory and oxidative stress markers in patients with vitiligo. J Clin Med 12(18):5861 Published 2023 Sep 9. https:\/\/doi.org\/10.3390\/jcm12185861","journal-title":"J Clin Med"},{"key":"3658_CR13","doi-asserted-by":"publisher","first-page":"1221260","DOI":"10.3389\/fimmu.2023.1221260","volume":"14","author":"P Yang","year":"2023","unstructured":"Yang P, Luan M, Li W et al (2023) Single-cell transcriptomics reveals peripheral immune responses in non-segmental vitiligo. Front Immunol 14:1221260 Published 2023 Nov 22","journal-title":"Front Immunol"},{"issue":"8","key":"3658_CR14","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/exd.14157","volume":"29","author":"PS Giri","year":"2020","unstructured":"Giri PS, Dwivedi M, Begum R (2020) Decreased suppression of CD8\u2009+\u2009and CD4\u2009+\u2009T cells by peripheral regulatory T cells in generalized vitiligo due to reduced NFATC1 and FOXP3 proteins. Exp Dermatol 29(8):759\u2013775. https:\/\/doi.org\/10.1111\/exd.14157","journal-title":"Exp Dermatol"},{"issue":"610","key":"3658_CR15","doi-asserted-by":"publisher","first-page":"eabd8995","DOI":"10.1126\/scitranslmed.abd8995","volume":"13","author":"KJ Gellatly","year":"2021","unstructured":"Gellatly KJ, Strassner JP, Essien K, Refat MA, Murphy RL, Coffin-Schmitt A et al (2021) scRNA-seq of human vitiligo reveals complex networks of subclinical immune activation and a role for CCR5 in T(reg) function. Sci Transl Med 13(610):eabd8995. https:\/\/doi.org\/10.1126\/scitranslmed.abd8995","journal-title":"Sci Transl Med"},{"key":"3658_CR16","doi-asserted-by":"publisher","first-page":"102859","DOI":"10.1016\/j.jaut.2022.102859","volume":"131","author":"J Chen","year":"2022","unstructured":"Chen J, Wang X, Cui T et al (2022) Th1-like Treg in vitiligo: an incompetent regulator in immune tolerance. J Autoimmun 131:102859. https:\/\/doi.org\/10.1016\/j.jaut.2022.102859","journal-title":"J Autoimmun"},{"issue":"4","key":"3658_CR17","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/pcmr.12105","volume":"26","author":"M Dwivedi","year":"2013","unstructured":"Dwivedi M, Laddha NC, Arora P, Marfatia YS, Begum R (2013) Decreased regulatory T-cells and CD4(+) \/CD8(+) ratio correlate with disease onset and progression in patients with generalized vitiligo. Pigment Cell Melanoma Res 26(4):586\u2013591. https:\/\/doi.org\/10.1111\/pcmr.12105","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"3658_CR18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/09546634.2020.1735615","volume":"33","author":"K Phan","year":"2022","unstructured":"Phan K, Phan S, Shumack S, Gupta M (2022) Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and meta-analysis. J Dermatolog Treat 33(1):173\u2013177. https:\/\/doi.org\/10.1080\/09546634.2020.1735615","journal-title":"J Dermatolog Treat"},{"issue":"11","key":"3658_CR19","doi-asserted-by":"publisher","first-page":"e15821","DOI":"10.1111\/dth.15821","volume":"35","author":"H Song","year":"2022","unstructured":"Song H, Hu Z, Zhang S, Yang L, Liu Y, Wang T (2022) Effectiveness and safety of tofacitinib combined with narrowband ultraviolet B phototherapy for patients with refractory vitiligo in real-world clinical practice. Dermatol Ther 35(11):e15821. https:\/\/doi.org\/10.1111\/dth.15821","journal-title":"Dermatol Ther"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03658-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03658-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03658-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T15:03:03Z","timestamp":1734706983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03658-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3658"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03658-x","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"24 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent for the publication of recognizable patient photographs was obtained by the authors before the submission to the journal stating that all patients gave consent with the understanding that this information maybe publicly available. Approval for the use of the photos and peripheral blood samples was obtained from the Ethical Committee of the Hospital for Skin Disease, Institute of Dermatology, Chinese Academy of Medical Sciences, and Peking Union Medical College, and the ethics approval code is 2024-KY-043.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}